Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $14.20.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.0% and a 50.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.
Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.13, representing a 69.9% upside.
In a report issued on April 24, Jefferies also maintained a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
Based on Epizyme’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $36.17 million. In comparison, last year the company had a GAAP net loss of $32.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers
